Zwj Investment Counsel 13F: Cuts AbbVie (ABBV) Stake by $1.8M
Zwj Investment Counsel reduced its holdings in AbbVie Inc. by 2.0%, according to its latest Form 13F filing with the SEC.
Reviewed by automated data checks against the source filing. How we make and check alerts
Zwj Investment Counsel sold 6,901 shares from its stake in AbbVie Inc. ($ABBV), a 2.02% decrease, according to a 13F filing with the SEC dated October 15, 2026. It reported 334,519 shares worth $87.51 million at the end of the quarter.
Since the filing, $ABBV is up 0.7% to date (from the $283.40 close on Oct 15, 2026).
Find the original: Zwj Investment Counsel 13F filings on SEC EDGAR
ABBV
AbbVie Inc.
Key Points
- Zwj Investment Counsel trimmed its AbbVie Inc. position by 2.0%, selling 6,901 shares to finish the reporting period with 334,519 shares valued at about $87.5 million.
- AbbVie shares trade around $285.52, well above their 50-day moving average of $255.68, backed by a forward P/E ratio of 16.3.
- A group of major Wall Street firms recently updated their outlooks on the stock, including JPMorgan maintaining its Overweight rating and raising its price target to $300.
Get $ABBV trade alerts by text
We text you when insiders, Congress or big funds trade $ABBV. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Zwj Investment Counsel trimmed its holdings in AbbVie Inc. NYSE: ABBV during the recent reporting period, reducing its exposure to the major drug maker. According to the firm's latest Form 13F filing with the Securities and Exchange Commission, the investment manager sold 6,901 shares, marking a 2.0% reduction in its position. The firm wrapped up the period with 334,519 shares of the healthcare giant, which carried an estimated value of $87,506,833. Institutional filings are backward-looking and capture holdings at a specific past date, meaning they may not reflect current trading activity.
Zwj Investment Counsel vs. the S&P 500
Hypothetical returns from Zwj Investment Counsel's disclosed trades, not real profit or advice. How we model this.
What Changed in Zwj Investment Counsel's AbbVie Position
Zwj Investment Counsel dialed back its investment after holding 341,420 shares prior to the adjustment. The reduction of 6,901 shares sliced 2.0% off the fund's total stake in the biopharmaceutical company. Even after trimming the position, AbbVie remains a notable holding for the counsel, reflecting active portfolio management as the stock trades near the higher end of its 52-week range.
Other Institutional Activity in AbbVie
Other large institutional investors also adjusted their positions in AbbVie during recent reporting windows. Blackrock Inc. grew its holdings by trimming 1,205,552 shares to end with 149,488,412 shares worth about $42.7 billion. Vanguard Capital Management LLC grew its holdings by 516,956 shares, ending with 115,396,098 shares worth about $33.0 billion. State Street Corporation grew its holdings by 1,380,673 shares, ending with 82,596,748 shares worth about $23.6 billion. Vanguard Portfolio Management LLC grew its holdings by trimming 1,044,934 shares, ending with 48,477,996 shares worth about $13.8 billion. JPMORGAN CHASE & CO grew its holdings by trimming 8,880,294 shares, ending with 47,862,796 shares worth about $13.7 billion.
AbbVie Inc. Stock Up 0.7%
AbbVie shares trade near $285.52, sitting comfortably above the 50-day moving average of $255.68 and the 200-day moving average of $229.80. The company commands a market capitalization of roughly $467.4 billion. Its trailing P/E ratio sits at 74.7, while its forward P/E ratio is a more modest 16.3 based on projected earnings. The stock has experienced a 52-week low of $190.75 and a 52-week high of $267.47.
Recent Earnings
AbbVie posted strong financial results for its latest period, generating $64.4 billion in revenue with a revenue growth rate of 10.2%. The company reported earnings per share of $3.54, accompanied by a net margin of 9.8% and a return on equity. The next quarterly earnings report is scheduled for October 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
Income-focused investors track AbbVie for its steady dividend program. The company pays an annual dividend rate of $6.92 per share, translating to a dividend yield of 2.62% with a payout ratio of 1.90.
Insider Buying and Selling at AbbVie Inc.
Company insiders have actively adjusted their stock ownership over recent months. On August 14, 2026, Officer Donoghoe Nicholas sold 32,710 shares at an average price of $250.00 for a total value of $8,177,500. Earlier in the year, on March 4, 2026, Officer Purdue David Ryan sold 5,230 shares at $233.56 worth $1,221,519. General Counsel Siatis Perry C. sold 18,668 shares on March 2, 2026, valued at $4,375,549, and previously sold 22,381 shares on February 25, 2026, at $230.00 for a total of $5,147,630. None of these transactions were reported as part of a Rule 10b5-1 trading plan.
Analysts Set New Price Targets
Wall Street research firms maintain an overall buy rating on AbbVie, supported by a mean price target of $278.61 across 28 analyst opinions. On October 13, 2026, RBC Capital reiterated its Outperform rating with a price target of $280.00. UBS maintained a Neutral rating on October 9, 2026, and raised its target from $260.00 to $275.00. Guggenheim reiterated a Buy rating on October 9, 2026, with a target of $288.00. JP Morgan maintained an Overweight rating on October 8, 2026, lifting its target from $285.00 to $300.00. Cantor Fitzgerald maintained an Overweight rating on October 8, 2026, raising its target from $285.00 to $290.00.
About AbbVie
AbbVie Inc. is a major research-focused biopharmaceutical enterprise that discovers, develops, and markets advanced medical treatments across multiple therapeutic areas. Its portfolio includes core therapies such as Skyrizi for autoimmune conditions, Rinvoq for inflammatory disorders, and cancer treatments like Imbruvica, Venclexta, Elahere, and Epkinly. The company's ongoing pipeline developments and steady commercial revenue play a central role in large institutional portfolios.
Bottom Line
Zwj Investment Counsel's decision to trim its AbbVie holding highlights active portfolio management as the stock trades at elevated levels. Investors should monitor the upcoming earnings release on October 29, 2026, for fresh updates on revenue growth and drug sales. Form 13F filings offer a retrospective look at institutional ownership trends rather than real-time indicators.
Related Filing Alerts
Source: Zwj Investment Counsel's 13F filing on $ABBV (Oct 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Zwj Investment Counsel 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts